The abstract is read at the publisher; the summary is JClub's.
In gnomADv4.1.1, in silico-driven curation for predicted pathogenic COL4A3/COL4A4 variants overestimated autosomal dominant Alport syndrome prevalence, yielding one in 221 instead of one in 106.
- Why it matters: The 2021 estimate may be inflated because triple-helical Glycine substitutions were classified as pathogenic using in silico tools, potentially misrepresenting true genetic prevalence.
- What they did: The study compared three curation strategies on gnomADv4.1.1 (~800,000 individuals, including UK Biobank) and a clinical exome cohort of 29,055 patients (KIDNEY: 8,663; NON-KIDNEY: 20,392), validating against controls and replicating in a non-UKB subset.
- The result: The Expert Strategy estimated one in 283 (validated in NON-KIDNEY: one in 295; concordance ratio 0.96), while Gibson inflated the control rate by 91% (one in 154 vs. one in 295), and Expert Strategy variants appeared in one in 44 KIDNEY patients (odds ratio 6.76).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.